Diagnosis and treatment of giant cell arteritis

References

• Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum. Dis. Clin. North Am.27(4), 729–749 (2001).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med.347(4), 261–271 (2002).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiological study. Medicine (Balt.)86(2), 61–68 (2007).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann. Intern. Med.123(3), 192–194 (1995).
   PubMed Web of Science ®Google Scholar
• Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxf.)38(12), 1208–1212 (1999).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo MP, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann. Rheum. Dis.60(4), 367–371 (2001).
   PubMed Web of Science ®Google Scholar
• Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br. J. Rheumatol.33(10), 938–941 (1994).
   PubMedGoogle Scholar
• Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum.42(5), 844–853 (1999).
   PubMed Web of Science ®Google Scholar
• Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann. Intern. Med.88(2), 162–167 (1978).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Balt.)84(5), 269–276 (2005).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am. J. Ophthalmol.125(4), 509–520 (1998).
   PubMed Web of Science ®Google Scholar
• Ghanchi FD, Dutton GN. Current concepts in giant cell (temporal) arteritis. Surv. Ophthalmol.42(2), 99–123 (1997).
   PubMed Web of Science ®Google Scholar
• Gur H, Rapman E, Ehrenfeld M, Sidi Y. Clinical manifestations of temporal arteritis: a report from Israel. J. Rheumatol.23(11), 1927–1931 (1996).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Llorca J et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Balt.)79(5), 283–292 (2000).
   PubMed Web of Science ®Google Scholar
• Keltner JL. Giant-cell arteritis. Signs and symptoms. Ophthalmology89(10), 1101–1110 (1982).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, Kardon RH.Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol. Scand.80(4), 355–367 (2002).
   PubMedGoogle Scholar
• Galetta SL, Balcer LJ, Liu GT. Giant cell arteritis with unusual flow-related neuro-ophthalmologic manifestations. Neurology49(5), 1463–1465 (1997).
   PubMedGoogle Scholar
• Pego-Reigosa R, Garcia-Porrua C, Piñeiro A et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin. Exp. Rheumatol.22(6 Suppl. 36), S13–S17 (2004).
   PubMed Web of Science ®Google Scholar
• Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum. Dis. Clin. North Am.19(4), 941–953 (1993).
   PubMed Web of Science ®Google Scholar
• Amor-Dorado JC, Llorca J, Garcia-Porrua C, Costa C, Perez-Fernandez N, Gonzalez-Gay MA. Audiovestibular manifestations in giant cell arteritis: a prospective study. Medicine (Balt.)82(1), 13–26 (2003).
   PubMed Web of Science ®Google Scholar
• Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr. Opin. Rheumatol.18(1), 10–17 (2006).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Blanco R, Sanchez-Andrade A, Vazquez-Caruncho M. Giant cell arteritis in Lugo, Spain: a more frequent disease with fewer classic features. J. Rheumatol.24(11), 2166–2170 (1997).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum.51(2), 274–277 (2004).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum.51(4), 652–655 (2004).
   PubMedGoogle Scholar
• Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum.33(8), 1122–1128 (1990).
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Blanco R, Armona J et al. Giant cell arteritis with an erythrocyte sedimentation rate lower than 50. Clin. Rheumatol.19(1), 73–75 (2000).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum.45(2), 140–145 (2001).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Balt.)84(5), 277–290 (2005).
   PubMed Web of Science ®Google Scholar
• Cid MC, Font C, Oristrell J et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum.41(1), 26–32 (1998).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cimino L, Macchioni P et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum.53(2), 293–297 (2005).
   PubMed Web of Science ®Google Scholar
• Parikh M, Miller NR, Lee AG et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology113(10), 1842–1845 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. The diagnosis and management of patients with giant cell arteritis. J. Rheumatol.32(7), 1186–1188 (2005).
   PubMed Web of Science ®Google Scholar
• Hall S, Hunder GG. Is temporal artery biopsy prudent? Mayo Clin. Proc.59(11), 793–796 (1984).
   PubMedGoogle Scholar
• Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum.33(8), 1074–1087 (1990).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin. Arthritis Rheum.30(4), 249–256 (2001).
   PubMed Web of Science ®Google Scholar
• Mahr A, Saba M, Kambouchner M et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann. Rheum. Dis.65(6), 826–828 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor-Gjevre R, Vo M, Shukla D, Resch L. Temporal artery biopsy for giant cell arteritis. J. Rheumatol.32(7), 1279–1282 (2005).
   PubMed Web of Science ®Google Scholar
• Ponge T, Barrier JH, Grolleau JY, Ponge A, Vlasak AM, Cottin S. The efficacy of selective unilateral temporal artery biopsy versus bilateral biopsies for diagnosis of giant cell arteritis. J. Rheumatol.15(6), 997–1000 (1988).
   PubMedGoogle Scholar
• Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann. Intern. Med.120(12), 987–992 (1994).
   PubMed Web of Science ®Google Scholar
• Font RL, Prabhakaran VC. Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases. Br. J. Ophthalmol.91(2), 204–209 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr. Opin. Rheumatol.17(1), 9–15 (2005).
   PubMed Web of Science ®Google Scholar
• Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann. Intern. Med.142(5), 359–369 (2005).
   PubMed Web of Science ®Google Scholar
• Narvaez J, Narvaez JA, Nolla JM, Sirvent E, Reina D, Valverde J. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxf.)44(4), 479–483 (2005).
   PubMed Web of Science ®Google Scholar
• Bley TA, Wieben O, Uhl M et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. Am. J. Roentgenol.184(1), 283–287 (2005).
   PubMed Web of Science ®Google Scholar
• Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal arteritis). Neurology38(3), 352–359 (1988).
   PubMed Web of Science ®Google Scholar
• Machado EBV Michet CJ, Ballard DJ et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950–1985. Arthritis Rheum.31(6), 745–749 (1988).
   PubMed Web of Science ®Google Scholar
• Foroozan R, Deramo VA, Buono LM et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology110(3), 539–542 (2003).
   PubMed Web of Science ®Google Scholar
• Neff AG, Greifenstein EM. Giant cell arteritis update. Semin. Ophthalmol.14(2), 109–12 (1999).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum.41(8), 1497–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Levine SM, Hellmann DB. Giant cell arteritis. Curr. Opin. Rheumatol.14(1), 3–10 (2002).
   PubMed Web of Science ®Google Scholar
• Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann. Intern. Med.82(5), 613–618 (1975).
   PubMed Web of Science ®Google Scholar
• Nesher G, Rubinow A, Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin. Exp. Rheumatol.15(3), 303–306 (1997).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J. Rheumatol.26(6), 1326–1332 (1999).
   PubMed Web of Science ®Google Scholar
• Amoli MM, Shelley E, Mattey DL et al. Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J. Rheumatol.29(3), 502–504 (2002).
   PubMed Web of Science ®Google Scholar
• Mazlumzadeh M, Hunder GG, Easley KA WL et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum.54(10), 3310–3318 (2006).
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin. Exp. Rheumatol.19(5), 495–501 (2001).
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.134(2), 106–114 (2001).
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum.46(5), 1309–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann. Rheum. Dis.55(4), 218–223 (1996).
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis.45(2), 136–138 (1986).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M. The quest for the ideal therapy for giant cell arteritis. Rev. Rhum. Engl. Ed.62(7–8), 539 (1995).
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum.44(12), 2933–2935 (2001).
   PubMed Web of Science ®Google Scholar
• Hoffman GC, Cid MC, Weyand CM et al. Phase II Study of the safety and efficacy of infliximab in giant cell arteritis (GCA): 22 week interim analysis. Arthritis Rheum.52(9 Suppl.), S271(663) (2005) (Abstract).
   Google Scholar
• Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Balt.)83(6), 342–347 (2004).
   PubMed Web of Science ®Google Scholar
• Nesher G, Berkun Y, Mates M et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum.50(4), 1332–1337 (2004).
   PubMed Web of Science ®Google Scholar
• Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum.54(10), 3306–3309 (2006).
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum.48(12), 3522–3531 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Balt.).83(6), 335–341 (2004).
   PubMed Web of Science ®Google Scholar
• Sambrook PN. How to prevent steroid induced osteoporosis. Ann. Rheum. Dis.64(2), 176–178 (2005).
   PubMed Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxf.)42(6), 743–749 (2003).
   PubMedGoogle Scholar
• Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J. Rheumatol.32(9), 1737–1741 (2005).
   PubMed Web of Science ®Google Scholar
• Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J. Rheumatol.25(11), 2140–2145 (1998).
   PubMedGoogle Scholar
• Gonzalez-Gay M. Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Res.3(3), 154–157 (2001).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin. Arthritis Rheum.33(1), 38–48 (2003).
   PubMed Web of Science ®Google Scholar